Skip to main content
. 2015 Jul 6;10(7):e0131566. doi: 10.1371/journal.pone.0131566

Fig 4. Incidence of adverse events during follow-up.

Fig 4

a Total: total percentage of patients with at least one adverse event; compared with CBZ, *: P<0.05, **: P<0.01; compared with VPA, #: P<0.05, ##: P<0.01; compared with TPM, &: P<0.05, &&: P<0.01; CBZ: carbamazepine; VPA: valproate; LTG: lamotrigine; TPM: topiramate; OXC: oxcarbazepine.